Mira Pharmaceuticals
Mira Pharmaceuticals
MIRA
NASDAQ
0.97
USD
0.00%
About
MIRA Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical development company. The Company has two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2, a patent pending oral ketamine analog under pre-clinical investigation to potentially deliver ultra-rapid antidepressant effects, providing hope for individuals battling treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDSI) and potentially post-traumatic stress disorder (PTSD).
Its oral pharmaceutical marijuana molecule, MIRA-55, is being studied for its potential to alleviate neuropathic pain, as well as anxiety and cognitive decline, symptoms commonly associated with early-stage dementia..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 4.1M |
| Three Month Average Volume | 117.1M |
| High Low | |
| Fifty-Two Week High | 6.59 USD |
| Fifty-Two Week Low | 0.51 USD |
| Fifty-Two Week High Date | 05 Sep 2023 |
| Fifty-Two Week Low Date | 03 Jul 2024 |
| Price and Volume | |
| Current Price | 1.93 USD |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | -15.81% |
| Thirteen Week Relative Price Change | 120.39% |
| Twenty-Six Week Relative Price Change | 68.79% |
| Fifty-Two Week Relative Price Change | -75.45% |
| Year-to-Date Relative Price Change | 55.22% |
| Price Change | |
| One Day Price Change | 3.21% |
| Thirteen Week Price Change | 135.88% |
| Twenty-Six Week Price Change | 85.59% |
| Five Day Price Change | 4.32% |
| Fifty-Two Week Price Change | -69.24% |
| Year-to-Date Price Change | 83.81% |
| Month-to-Date Price Change | -8.10% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.29595 USD |
| Book Value Per Share (Most Recent Quarter) | 0.15012 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.29595 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.15012 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.61774 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.81066 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.85618 USD |
| Normalized (Last Fiscal Year) | -0.81066 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.81066 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.85618 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.81066 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.85618 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.31139 USD |
| Cash Per Share (Most Recent Quarter) | 0.19104 USD |
| Cash Flow Per Share (Last Fiscal Year) | -99999.99 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -99999.99 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.29947 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -33.26% |
| EPS Change (Trailing Twelve Months) | -99,999.99% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 7 |
| Price to Tangible Book (Most Recent Quarter) | 13 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -2,823,780 |
| Net Debt (Last Fiscal Year) | -4,602,570 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 7 |
| Price to Book (Most Recent Quarter) | 13 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 9 |
| Current Ratio (Most Recent Quarter) | 4 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -4,532,400 |
| Free Cash Flow (Trailing Twelve Months) | -4,709,750 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -2 |
| Net Interest Coverage (Trailing Twelve Months) | -3 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -413.86% |
| Return on Assets (Trailing Twelve Months) | -373.77% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -634.30% |
| Return on Equity (Trailing Twelve Months) | -748.59% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -620.46% |
| Return on Investment (Trailing Twelve Months) | -737.47% |
| Return on Investment (5 Year) | -99,999.99% |